Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Common Equity (2016 - 2025)

Historic Common Equity for RedHill Biopharma (RDHL) over the last 15 years, with Q2 2025 value amounting to -$4.4 million.

  • RedHill Biopharma's Common Equity fell 733278.69% to -$4.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$4.4 million, marking a year-over-year decrease of 733278.69%. This contributed to the annual value of -$4.7 million for FY2024, which is 32634.12% down from last year.
  • As of Q2 2025, RedHill Biopharma's Common Equity stood at -$4.4 million, which was down 733278.69% from -$4.7 million recorded in Q4 2024.
  • Over the past 5 years, RedHill Biopharma's Common Equity peaked at $53.0 million during Q1 2021, and registered a low of -$48.4 million during Q4 2022.
  • Its 5-year average for Common Equity is -$1.3 million, with a median of -$2.2 million in 2024.
  • Per our database at Business Quant, RedHill Biopharma's Common Equity surged by 10427.48% in 2023 and then tumbled by 733278.69% in 2025.
  • Over the past 5 years, RedHill Biopharma's Common Equity (Quarter) stood at $8.9 million in 2021, then crashed by 645.35% to -$48.4 million in 2022, then surged by 104.27% to $2.1 million in 2023, then crashed by 326.34% to -$4.7 million in 2024, then grew by 5.79% to -$4.4 million in 2025.
  • Its last three reported values are -$4.4 million in Q2 2025, -$4.7 million for Q4 2024, and $61000.0 during Q2 2024.